Acrobiosystems Co.,Ltd.

XSEC:301080 Stock Report

Market Cap: CN¥10.3b

AcrobiosystemsLtd Valuation

Is 301080 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 301080 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: 301080 (CN¥61.49) is trading below our estimate of fair value (CN¥62.99)

Significantly Below Fair Value: 301080 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301080?

Key metric: As 301080 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301080. This is calculated by dividing 301080's market cap by their current earnings.
What is 301080's PE Ratio?
PE Ratio59.3x
EarningsCN¥172.77m
Market CapCN¥10.25b

Price to Earnings Ratio vs Peers

How does 301080's PE Ratio compare to its peers?

The above table shows the PE ratio for 301080 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average76.8x
000534 Wedge IndustrialLtd
49.2x34.46%CN¥11.0b
300685 Amoy Diagnostics
30x20.07%CN¥8.7b
301047 Sino BiologicalInc
71.3x17.36%CN¥9.5b
688319 Chengdu Olymvax Biopharmaceuticals
156.5x14.42%CN¥10.0b
301080 AcrobiosystemsLtd
59.3x28.82%CN¥10.3b

Price-To-Earnings vs Peers: 301080 is good value based on its Price-To-Earnings Ratio (59.3x) compared to the peer average (76.8x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 301080's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
301080 59.3xIndustry Avg. 50.9xNo. of Companies5PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 301080 is expensive based on its Price-To-Earnings Ratio (59.3x) compared to the CN Biotechs industry average (50.9x).

Price to Earnings Ratio vs Fair Ratio

What is 301080's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301080 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio59.3x
Fair PE Ratio33.2x

Price-To-Earnings vs Fair Ratio: 301080 is expensive based on its Price-To-Earnings Ratio (59.3x) compared to the estimated Fair Price-To-Earnings Ratio (33.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 301080 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥61.49
CN¥76.35
+24.17%
8.56%CN¥88.00CN¥69.00n/a5
Jan ’27CN¥54.00
CN¥79.25
+46.77%
15.14%CN¥102.50CN¥69.00n/a5
Dec ’26CN¥56.42
CN¥79.25
+40.47%
15.14%CN¥102.50CN¥69.00n/a5
Nov ’26CN¥64.77
CN¥77.92
+20.31%
16.38%CN¥102.50CN¥68.12n/a5
Oct ’26CN¥59.56
CN¥63.04
+5.85%
18.64%CN¥72.20CN¥42.86n/a4
Sep ’26CN¥59.83
CN¥56.57
-5.44%
24.88%CN¥72.20CN¥42.24n/a4
Aug ’26CN¥54.80
CN¥42.12
-23.14%
1.36%CN¥42.86CN¥41.25n/a4
Jul ’26CN¥51.87
CN¥42.12
-18.80%
1.36%CN¥42.86CN¥41.25n/a4
Jun ’26CN¥37.50
CN¥42.12
+12.32%
1.36%CN¥42.86CN¥41.25n/a4
May ’26CN¥34.21
CN¥42.08
+23.02%
1.56%CN¥42.86CN¥41.25n/a3
Apr ’26CN¥38.99
CN¥35.05
-10.08%
1.68%CN¥35.71CN¥34.29n/a3
Mar ’26CN¥37.87
CN¥35.05
-7.44%
1.68%CN¥35.71CN¥34.29n/a3
Feb ’26CN¥34.96
CN¥35.05
+0.28%
1.68%CN¥35.71CN¥34.29n/a3
Jan ’26CN¥31.53
CN¥35.05
+11.18%
1.68%CN¥35.71CN¥34.29CN¥54.003
Dec ’25CN¥31.25
CN¥34.22
+9.51%
4.46%CN¥35.71CN¥31.73CN¥56.424
Nov ’25CN¥28.29
CN¥32.62
+15.31%
7.05%CN¥35.16CN¥29.29CN¥64.774
Oct ’25CN¥30.21
CN¥33.52
+10.95%
10.49%CN¥38.79CN¥29.29CN¥59.564
Sep ’25CN¥23.80
CN¥40.49
+70.11%
24.56%CN¥57.14CN¥31.73CN¥59.834
Aug ’25CN¥25.30
CN¥40.55
+60.29%
24.49%CN¥57.14CN¥31.73CN¥54.804
Jul ’25CN¥25.13
CN¥40.55
+61.38%
24.49%CN¥57.14CN¥31.73CN¥51.874
Jun ’25CN¥27.99
CN¥40.55
+44.91%
24.49%CN¥57.14CN¥31.73CN¥37.504
May ’25CN¥27.59
CN¥36.67
+32.90%
6.51%CN¥39.06CN¥34.29CN¥34.212
Apr ’25CN¥29.87
CN¥57.56
+92.70%
5.30%CN¥62.64CN¥54.84CN¥38.994
Mar ’25CN¥31.79
CN¥57.56
+81.10%
5.30%CN¥62.64CN¥54.84CN¥37.874
Feb ’25CN¥28.51
CN¥57.56
+101.87%
5.30%CN¥62.64CN¥54.84CN¥34.964
Jan ’25CN¥42.10
CN¥57.56
+36.73%
5.30%CN¥62.64CN¥54.84CN¥31.534
CN¥76.35
Fair Value
19.5% undervalued intrinsic discount
5
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/16 01:18
End of Day Share Price 2026/01/16 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Acrobiosystems Co.,Ltd. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yuan GaoChina International Capital Corporation Limited
Shiyu ChenChina International Capital Corporation Limited